Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Estey

Showing results (111-120 of 204) with videos related to

Pageof 21
Sort By:
Cancer|November 15, 1993
Granulocyte colony-stimulating factor supportive treatment following intensive chemotherapy in acute lymphocytic leukemia in first remissionH M Kantarjian, E Estey, S O'Brien, et al.
The New England Journal of Medicine|February 3, 1994
Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapyS O'Brien, H Kantarjian, E Estey, et al.
The American Journal of Medicine|April 29, 1998
Comparison of referring and tertiary cancer center physician's diagnoses in patients with leukemiaM DeLima, M Albitar, S O'Brien, et al.
Blood|June 1, 1993
Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agentM J Keating, S O'Brien, H Kantarjian, et al.
Experimental Hematology|January 1, 1993
Ubiquitous expression of cytokines in diverse leukemias of lymphoid and myeloid lineageR Kurzrock, H Kantarjian, M Wetzler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1997
Second cancer risk in hairy cell leukemia: analysis of 350 patientsR Kurzrock, S S Strom, E Estey, et al.
Leukemia|January 1, 1992
Evolution of treatment for acute myelogenous leukemia and myelodysplastic syndrome at M.D. Anderson Cancer Center 1985-1991M J Keating, E Estey, H Kantarjian, et al.
Cancer|December 11, 1999
A phase I-II trial of escalating doses of mitoxantrone with fixed doses of cytarabine plus fludarabine as salvage therapy for patients with acute leukemia and the blastic phase of chronic myelogenous leukemiaC A Koller, H M Kantarjian, E J Feldman, et al.
The American Journal of Medicine|January 1, 1993
Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosisP M Derderian, H M Kantarjian, M Talpaz, et al.
Biochemical Pharmacology|December 1, 1987
Effect of 1-beta-D-arabinofuranosylcytosine (ara-C) on nuclear topoisomerase II activity and on the DNA cleavage and cytotoxicity produced by 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) and etoposide in m-AMSA-sensitive and -resistant human leukemia cellsM Bakic, D Chan, B S Andersson, et al.
Pageof 21

Showing results (111-120 of 204) with videos related to

Sort By:
Pageof 21
Cancer|November 15, 1993
Granulocyte colony-stimulating factor supportive treatment following intensive chemotherapy in acute lymphocytic leukemia in first remissionH M Kantarjian, E Estey, S O'Brien, et al.
The New England Journal of Medicine|February 3, 1994
Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapyS O'Brien, H Kantarjian, E Estey, et al.
The American Journal of Medicine|April 29, 1998
Comparison of referring and tertiary cancer center physician's diagnoses in patients with leukemiaM DeLima, M Albitar, S O'Brien, et al.
Blood|June 1, 1993
Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agentM J Keating, S O'Brien, H Kantarjian, et al.
Experimental Hematology|January 1, 1993
Ubiquitous expression of cytokines in diverse leukemias of lymphoid and myeloid lineageR Kurzrock, H Kantarjian, M Wetzler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1997
Second cancer risk in hairy cell leukemia: analysis of 350 patientsR Kurzrock, S S Strom, E Estey, et al.
Leukemia|January 1, 1992
Evolution of treatment for acute myelogenous leukemia and myelodysplastic syndrome at M.D. Anderson Cancer Center 1985-1991M J Keating, E Estey, H Kantarjian, et al.
Cancer|December 11, 1999
A phase I-II trial of escalating doses of mitoxantrone with fixed doses of cytarabine plus fludarabine as salvage therapy for patients with acute leukemia and the blastic phase of chronic myelogenous leukemiaC A Koller, H M Kantarjian, E J Feldman, et al.
The American Journal of Medicine|January 1, 1993
Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosisP M Derderian, H M Kantarjian, M Talpaz, et al.
Biochemical Pharmacology|December 1, 1987
Effect of 1-beta-D-arabinofuranosylcytosine (ara-C) on nuclear topoisomerase II activity and on the DNA cleavage and cytotoxicity produced by 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) and etoposide in m-AMSA-sensitive and -resistant human leukemia cellsM Bakic, D Chan, B S Andersson, et al.
Pageof 21